SAN DIEGO, Feb. 10, 2024 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) securities between November 11, 2022 and November 8, 2023, inclusive (the "Class Period"), have until April 9, 2024 to seek appointment as lead plaintiff of the Amylyx class action lawsuit. Captioned Shih v. Amylyx Pharmaceuticals, Inc., No. 24-cv-00988 (S.D.N.Y.), the Amylyx class action lawsuit charges Amylyx and certain of Amylyx's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Amylyx class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-amylyx-pharmaceuticals-inc-class-action-lawsuit-amlx.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at.